Little Rhody’s sixth new medical license will have to wait until the new year
The fate of Rhode Island’s final medical cannabis license will likely remain unknown into 2022.
Coverage of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.
The fate of Rhode Island’s final medical cannabis license will likely remain unknown into 2022.
The Vermont Cannabis Control Board released their recommendations during its Dec. 10 meeting, for code compliance and penalties in the state’s upcoming adult-use cannabis market.
Consumers have a strong preference for strong cannabis in Massachusetts, making it more difficult for cultivators in the wholesale market to move product with lower THC concentrations.
Cannabis delivery is supposed to be reserved for social equity applicants in Mass., but larger companies are finding a way.
Conn. regulators opted to delay final approval on its technical assistance accelerator program so that it can find a consensus on its details at an as-yet-unscheduled special hearing.
A recent hearing before the New Hampshire Cannabis Therapeutic Oversight Board brought a series of complaints from patients that local dispensary prices remain too high for regular customers.
One more Massachusetts cannabis company challenged the validity of required community impact fees as dispensary Happy Valley filed suit against the City of Gloucester.
Maine’s Medical Marijuana Work Group is still searching for consensus on testing standards.
There is a new coalition in Connecticut that seeks to promote social equity in cannabis.
Connecticut, New Hampshire, and Vermont do not currently report nor collect sales figures for legal cannabis.